Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells: Potential role of p53 in regulation of vascular smooth muscle cell growth

Hypertension

Volumn 34, Issue 2, 1999, Pages 192-200

  Aoki, Motokuni ^a   Morishita, Ryuichi ^a   Matsushita, Hidetsugu ^a   Hayashi, Shin Ichiro ^a   Nakagami, Hironori ^a   Yamamoto, Kei ^a   Moriguchi, Atsushi ^a   Kaneda, Yasufumi ^a   Higaki, Jitsuo ^a   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Antisense; Apoptosis; Genes; Muscle, smooth, vascular; Restenosis

Indexed keywords

OLIGODEOXYNUCLEOTIDE; PROTEIN P53; TUBULIN;

AORTA MEDIA; APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RESTENOSIS; SMOOTH MUSCLE FIBER; TUMOR SUPPRESSOR GENE; VASCULAR SMOOTH MUSCLE;

EID: 0032856493     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.34.2.192     Document Type: Article

References (39)

1. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;30:1431-1438.
2. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature. 1992;358:259-261.
3. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihar T, Dzau VJ. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8478.
4. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Leyen HVL, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimai hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-1464.
5. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855-5859.
6. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
7. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell. 1992;70: 523-526.
8. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992;258:424-429.
9. Lane DP. p53, guardian of the genome. Nature. 1992;258:15-16.
10. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Dyke TV. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78:703-711.
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzeler KW, Vogelstein B. WAF 1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
12. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265:391-394.
13. Tsai HL, Kou GH, Chen SC, Wu CW, Lin YS. Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J Biol Chem. 1996;271:3534-3540.
14. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
15. Bonin PD, Leadley RJ, Erickson LA. Growth factor-induced modulation of endothelial-1 binding to human smooth muscle cells. J Cardiovasc Pharmacol. 1993;22:S125-S127.
16. Bi S, Lanza F, Goldman JM. The involvement of "tumor suppressor" p53 in normal and chronic myclogenous leukemia hemopoiesis. Cancer Res. 1994;54:582-586.
17. Hatzfeld J, Li ML, Brown EL, Sookdeo H, Levesque JP, O'Toole TM, Gurney C, Clark SC, Hatzfeld A. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β1 or Rb oligonucleotides. J Exp Med. 1991;174:925-929.
18. Libby P, O'Brien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983;115:217-223.
19. Morishita R, Gibbons GH, Pratt RE, Tomita N, Kaneda Y, Ogihara T, Dzau VJ. Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest. 1994;94:824-829.
20. Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M, He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull (Tokyo). 1993;41:1118-1122.
21. Bennett MR, Evan GI, Newby AC. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotides analogues and induces apoptosis. Circ Res. 1994;74:525-536.
22. Bennett MR, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:2266-2274.
23. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis: countervailing influences of nitric oxide and angiotensin II. Circ Res. 1996;79:748-756.
24. Aoki M, Morishita R, Matsushita H, Nakano N, Hayashi S, Tomita N, Yamamoto K, Moriguchi A, Higaki J, Ogihara T. Serum deprivation induced apoptosis accompanied by up-regulalion of p53 and bax in human aortic vascular smooth muscle cells. Heart Vessels. 1997;S12: 71-75.
25. Ito M, Watanabe M, Ihara T, Kamiya H, Sakurai M. Fas antigen and bcl-2 expression on lymphocytes cultured with cytomegalovirus and varicella-zoster virus antigen. Cell Immunol. 1995;160:173-177.
26. Raff M. Social controls on cell survival and cell death. Nature. 1992; 356:397-400.
27. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995;91:2703-2711.
28. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma: colocalization with interleukin-1-β-converting enzyme. Am J Pathol. 1995;147:251-266.
29. Han DKM, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995;147:267-277.
30. Cho A, Courtman DW, Langille BL. Apoptosis (programmed cell death) in arteries of the neonatal lamb. Circ Res. 1995;76:168-175.
31. Bochaton-Piallat ML, Gabbiani F, Redard M, Desmouliere A, Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol. 1995;146:1059-1064.
32. Bennett MR, Macdonald K, Chan SW, Boyle JJ, Weissberg PL. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ Res. 1998;82:704-712.
33. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 1991;371:72-74.
34. Qin XQ, Livingston DM, Kaelin WG, Adams PD. Deregulated transcriptional factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A. 1994;91:10918-10922.
35. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
36. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
37. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124:1-6.
38. Bennett MR, Evan GI, Schwartz SM. Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways. Circ Res. 1995;77:266-273.
39. Johnson TM, Epstein SE, Finkel T. Species-specific induction of apoptosis in normal vascular smooth muscle cells using an adenoviral expressing human p53. Circulation. 1996;94:I-155. Abstract.